RxDoctor Payments Data

Nhan Nguyen, MD

Interventional Cardiology · Richardson, TXNPI 1124082128

Payments from drug & device makers

$62,387in general payments, 2019–2025

Across 387 payments — averaging $161.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$33K
  • Edwards Lifesciences$15K
  • Osprey Medical Inc$3K
  • Medtronic$3K
  • Boston Scientific$2K
  • Philips North America LLC$1K
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$12,75038%
  • Speaking & faculty fees$3,50011%
  • Travel & lodging$3,0639%
  • Food & beverage$13,79642%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,387 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$296,977
Medicare patients
1,506
Services billed
5,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban584$704,068
EntrestoSacubitril/Valsartan121$168,454
XareltoRivaroxaban97$143,528
JardianceEmpagliflozin29$47,058
FarxigaDapagliflozin Propanediol21$31,483
Repatha SureclickEvolocumab27$21,636
Metoprolol Succinate481$5,596
Atorvastatin Calcium399$4,225
ClopidogrelClopidogrel Bisulfate318$3,974
Carvedilol357$3,082
Lisinopril250$2,815
Amlodipine Besylate405$2,505
Flecainide Acetate67$2,505
Nifedipine ErNifedipine97$2,501
Losartan Potassium211$1,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$278$704,068584 claims
NovartisEntresto$322$168,454121 claims
Johnson & JohnsonXarelto$346$143,52897 claims
Boehringer IngelheimJardiance$55$47,05829 claims
AstraZenecaFarxiga$14$31,48321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →